Glanbia Nutritionals expands vitamin K2 distribution agreement into Europe

摘要

Glanbia Nutritionals, a global ingredient solutions and nutritional premix provider, has widened the scope of its distribution agreement with Norway-based NattoPharma ASA, a worldwide innovator and pioneer of Vitamin K2. In addition to the US and Canada, Clanbia Nutritionals has the distribution rights for NattoPharma's MenaQ7~® PURE Vitamin K2 (MK7) in Europe and the Middle East. A nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7), MenaQ7 PURE is the first-in-class, only clinically researched vitamin K2 MK-7. Supported by a global IP portfolio and revolutionary research substantiating clear efficacy for bone health and an important association with arterial health, MenaQ7 PURE is the optimal ingredient supporting the targeted use of calcium in the body. It activates osteocalcin that helps to bind calcium to the bone matrix, and may also be linked with 'cleaning up' calcium in the arteries. Studies on supplementation with MenaQ7 PURE show that MK-7 may improve arterial flexibility. A three-year study on 244 healthy women taking MenaQ7 PURE showed statistically significant protection of the vertebrae and the hip (femoral neck) from bone loss.